Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
<p><i>Objective</i> Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabling relapses leading to high morbidity and mortality. Understanding relapse activity and severity is important for treatment decisions and clinical trial design. We assess...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2016
|
| _version_ | 1826305116165111808 |
|---|---|
| author | Tackley, G O'Brien, F Rocha, J Woodhall, M Waters, P Chandratre, S Halfpenny, C Hemingway, C Wassmer, E Wasiewski, W Leite, M Palace, J |
| author_facet | Tackley, G O'Brien, F Rocha, J Woodhall, M Waters, P Chandratre, S Halfpenny, C Hemingway, C Wassmer, E Wasiewski, W Leite, M Palace, J |
| author_sort | Tackley, G |
| collection | OXFORD |
| description | <p><i>Objective</i> Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabling relapses leading to high morbidity and mortality. Understanding relapse activity and severity is important for treatment decisions and clinical trial design. We assessed (1) whether clinical and demographic factors associate with different relapse rates and (2) the relative impact of immunosuppressive treatments on relapse rates and on attack-related residual disability.</p> <p><i>Methods</i> Clinical, demographic and treatment data were prospectively collected from 79 consecutive aquaporin 4 antibody positive patients seen in the nationally commissioned Oxford NMO service. The influence of clinical features on annualised relapse rates (using multiple regression) and the effect of immunosuppression on relapse-associated residual disability for transverse myelitis and optic neuritis attacks (using a mixed effect model) were analysed.</p> <p><i>Results</i> The mean annualised relapse rate was 0.93. Relapse rates were significantly higher in Afro-Caribbeans, children and in those of shorter disease duration. Relapse rates reduced on treatment (from 0.87 to 0.42). Delay to first treatment did not influence eventual on-treatment relapse rate. Immunosuppressive treatment significantly reduced the residual disability from ON (<i>p</i><0.01), and TM (<i>p</i>=0.029) attacks.</p> <p><i>Conclusions</i> Relapse rates in NMO are influenced by multiple factors, including age, ethnicity and disease duration. Current immunosuppressive treatments reduce but do not abolish relapses, however, they appear to additionally lessen the chronic disabling effect of a relapse.</p> |
| first_indexed | 2024-03-07T06:27:59Z |
| format | Journal article |
| id | oxford-uuid:f4fb1467-62b0-4eaf-95e6-dd587346031c |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:27:59Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:f4fb1467-62b0-4eaf-95e6-dd587346031c2022-03-27T12:23:53Z Neuromyelitis optica relapses: race and rate, immunosuppression and impairment Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f4fb1467-62b0-4eaf-95e6-dd587346031cSymplectic Elements at OxfordElsevier2016Tackley, GO'Brien, FRocha, JWoodhall, MWaters, PChandratre, SHalfpenny, CHemingway, CWassmer, EWasiewski, WLeite, MPalace, J <p><i>Objective</i> Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabling relapses leading to high morbidity and mortality. Understanding relapse activity and severity is important for treatment decisions and clinical trial design. We assessed (1) whether clinical and demographic factors associate with different relapse rates and (2) the relative impact of immunosuppressive treatments on relapse rates and on attack-related residual disability.</p> <p><i>Methods</i> Clinical, demographic and treatment data were prospectively collected from 79 consecutive aquaporin 4 antibody positive patients seen in the nationally commissioned Oxford NMO service. The influence of clinical features on annualised relapse rates (using multiple regression) and the effect of immunosuppression on relapse-associated residual disability for transverse myelitis and optic neuritis attacks (using a mixed effect model) were analysed.</p> <p><i>Results</i> The mean annualised relapse rate was 0.93. Relapse rates were significantly higher in Afro-Caribbeans, children and in those of shorter disease duration. Relapse rates reduced on treatment (from 0.87 to 0.42). Delay to first treatment did not influence eventual on-treatment relapse rate. Immunosuppressive treatment significantly reduced the residual disability from ON (<i>p</i><0.01), and TM (<i>p</i>=0.029) attacks.</p> <p><i>Conclusions</i> Relapse rates in NMO are influenced by multiple factors, including age, ethnicity and disease duration. Current immunosuppressive treatments reduce but do not abolish relapses, however, they appear to additionally lessen the chronic disabling effect of a relapse.</p> |
| spellingShingle | Tackley, G O'Brien, F Rocha, J Woodhall, M Waters, P Chandratre, S Halfpenny, C Hemingway, C Wassmer, E Wasiewski, W Leite, M Palace, J Neuromyelitis optica relapses: race and rate, immunosuppression and impairment |
| title |
Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
|
| title_full |
Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
|
| title_fullStr |
Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
|
| title_full_unstemmed |
Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
|
| title_short |
Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
|
| title_sort | neuromyelitis optica relapses race and rate immunosuppression and impairment |
| work_keys_str_mv | AT tackleyg neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT obrienf neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT rochaj neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT woodhallm neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT watersp neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT chandratres neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT halfpennyc neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT hemingwayc neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT wassmere neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT wasiewskiw neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT leitem neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment AT palacej neuromyelitisopticarelapsesraceandrateimmunosuppressionandimpairment |